COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Background: Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods: The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results: The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions: This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However, improved COVID-19 prevention has reduced mortality despite an increase in the number of reported cases.EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223)

Acoustic telemetry reveals strong spatial preferences and mixing during successive spawning periods in a partially migratory common bream population

Partial migration, whereby a population comprises multiple behavioural phenotypes that each have varying tendencies to migrate, is common among many animals. Determining the mechanisms by which these phenotypes are maintained is important for understanding their roles in population structure and stability. The aim here was to test for the temporal and spatial consistency of migratory phenotypes in a common bream Abramis brama (‘bream’) population, and then determine their social preferences and extent of mixing across three successive annual spawning periods. The study applied passive acoustic telemetry to track the movements of bream in the River Bure system of the Norfolk Broads, a lowland wetland comprising highly connected riverine and lacustrine habitats. Analyses revealed that individual migratory phenotype was highly consistent across the three years, but this was not predicted by fish sex or length at tagging. During the annual spawning periods, network analyses identified off-channel areas visited by both resident and migrant fish that, in non-spawning periods, were relatively independent in their space use. Within these sites, the co-occurrence of bream was non-random, with individuals forming more preferred and avoided associations than expected by chance. These associations were not strongly predicted by similarity in fish length, sex or behavioural phenotype, indicating that the resident and migrant phenotypes mixed during their annual spawning periods. The results suggested these different phenotypes, with spatially distinct resource use in non-spawning periods, comprised a single metapopulation, with this having important implications for the management of this wetland resource

Extrasolar enigmas: from disintegrating exoplanets to exoasteroids

Thousands of transiting exoplanets have been discovered to date, thanks in great part to the {\em Kepler} space mission. As in all populations, and certainly in the case of exoplanets, one finds unique objects with distinct characteristics. Here we will describe the properties and behaviour of a small group of `disintegrating' exoplanets discovered over the last few years (KIC 12557548b, K2-22b, and others). They evaporate, lose mass unraveling their naked cores, produce spectacular dusty comet-like tails, and feature highly variable asymmetric transits. Apart from these exoplanets, there is observational evidence for even smaller `exo-'objects orbiting other stars: exoasteroids and exocomets. Most probably, such objects are also behind the mystery of Boyajian's star. Ongoing and upcoming space missions such as {\em TESS} and PLATO will hopefully discover more objects of this kind, and a new era of the exploration of small extrasolar systems bodies will be upon us.Comment: Accepted for publication in the book "Reviews in Frontiers of Modern Astrophysics: From Space Debris to Cosmology" (eds Kabath, Jones and Skarka; publisher Springer Nature) funded by the European Union Erasmus+ Strategic Partnership grant "Per Aspera Ad Astra Simul" 2017-1-CZ01-KA203-03556

Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Peer reviewe

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals, and monoclonal antibodies have been effective for the general population, their benefits for these patients may not be as pronounced.Peer reviewe